Related Experiment Video
Updated: Feb 23, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Noninvasive Imaging of Ras Activity by Monomolecular Biosensor Based on Split-Luciferase Complementary Assay
Liang Chen1, Wei Bing Leng1,2, De Zhi Li1,2
1Laboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Researchers developed a novel bioluminescent biosensor to monitor Ras GTPase activity in living subjects. This tool offers a sensitive, noninvasive method for cancer research and drug screening.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ras GTPases play a crucial role in human cancer development.
- Monitoring Ras activity in vivo is essential for understanding tumorigenesis and developing targeted therapies.
- Existing methods for Ras activity assessment are often invasive and lack sensitivity.
Purpose of the Study:
- To develop a novel monomolecular bioluminescent biosensor for imaging endogenous Ras activity in living subjects.
- To establish a sensitive and noninvasive tool for real-time monitoring of Ras signaling.
- To facilitate high-throughput screening of Ras-targeted therapeutics.
Main Methods:
- Utilized a split firefly luciferase complementation strategy.
- Engineered a biosensor where luciferase fragments are linked by Raf-1, which changes conformation upon GTP-Ras binding.
- Validated the biosensor's performance in living colorectal cancer cells and in vivo models.
Main Results:
- The developed biosensor demonstrated robust and sensitive reporting of dynamic Ras activity.
- Bioluminescence intensity directly correlated with endogenous Ras activity levels.
- The sensor provided a faster, simpler, and more sensitive alternative to traditional pull-down assays.
Conclusions:
- The novel bioluminescent biosensor enables effective in vivo imaging of Ras activity.
- This technology facilitates preclinical evaluation of cancer therapies targeting the Ras pathway.
- The biosensor is a valuable tool for drug discovery and personalized medicine in oncology.
More Related Videos
09:09Author Spotlight: Regulation and Dysregulation of ER-Mitochondria Contacts — Implications for Neurodegenerative Disease Pathogenesis
Published on: October 11, 2024
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024